Livmarli now approved in US for PFIC patients 1 year and older
The U.S. Food and Drug Administration (FDA) has approved a label expansion for Livmarli (maralixibat) that allows the medication to be used in patients with…
The use of dupilumab, an approved anti-inflammatory antibody-based treatment, worked to ease itching, known medically as pruritus, in a young woman with Alagille syndrome after several other anti-itch medications had failed, a study reported. Dupilumab is prescribed in the U.S., under the brand name Dupixent, for treating certain…
Read MoreThe U.S. Food and Drug Administration (FDA) has approved a label expansion for Livmarli (maralixibat) that allows the medication to be used in patients with…
World Hepatitis Day, marked annually on July 28, seeks to raise awareness and help efforts to end viral hepatitis, a condition marked by liver…
NGM Biopharmaceuticals has raised $122 million in financing, which the California-based company will use to help launch a planned registrational clinical trial to test…